safety and immunogenicity of v116 in vaccine-naïve japanese older adults (v116-009, stride-9)

Conditions: Pneumococcal Disease

Summary: this is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of v116 in pneumococcal vaccine-naïve japanese adults 65 years of age and older. the polyvalent (23-valent) pneumococcal vaccine, ppsv23, is the active comparator. in addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of v116 is noninferior to ppsv23 for the 12 common serotypes in v116 and ppsv23 and the cross-reactive serotype 15b in v116, and that the immunogenicity of v116 is superior to ppsv23 for the unique serotype 15c in v116. it is also hypothesized that v116 is superior to ppsv23 in the percentage of participants with ≥4-fold rise from baseline in the 8 unique v116 serotypes (except for 15c), as measured by serotype-specific opsonophagocytic activity (opa) geometric mean titers (gmts).


Eligibility criteria:
inclusion criteria: * is japanese * for females, is not pregnant or breastfeeding and is either not a participant of childbearing potential (pocbp) or is a pocbp and uses acceptable contraception/abstinence; has a negative highly sensitive pregnancy test (urine or serum) within 24 (urine) or 72 (serum) hours before the first dose of study intervention; and has medical, menstrual, and recent sexual activity history reviewed by the investigator to decrease the chance of inclusion of an early undetected pregnancy exclusion criteria: * has a history of invasive pneumococcal disease (ipd) \[positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site\] or known history of other culture-positive pneumococcal disease within 3 years of visit 1 (day 1) * has a known hypersensitivity to any component of v116 or ppsv23, including diphtheria toxoid * has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (hiv) infection, functional or anatomic asplenia, or history of autoimmune disease * has a coagulation disorder contraindicating im vaccination * had a recent febrile illness (defined as oral or tympanic temperature ≥100.4°f \[≥38.0°c\] or axillary or temporal temperature ≥99.4°f \[≥37.4°c\]) or received antibiotic therapy for any acute illness occurring \<72 hours before receipt of study vaccine * has a known malignancy that is progressing or has required active treatment \<3 years before enrollment * received prior pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol * received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention ≥14 days before receipt of study vaccine * is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease * received any nonlive vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤30 days after receipt of study vaccine (inactivated influenza and sars-cov2 vaccines may be acceptable) * received any live virus vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine * received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the day 30 postvaccination blood draw is complete